“Our government is working around the clock to ensure that there is a fair and equitable distribution of vaccines, once they are ready. Our top priority is how to ensure the vaccine for everyone and everyone in the country,” Vardhan said while interacted with social media. users during Sunday Samvaad-4.
“There is a high-level body of expertise that deals with all aspects of vaccines. Our estimate and goal would be to receive and use between 400 and 500 million doses covering approximately 25 million people by July 2021.” He said.
Currently, two candidate vaccines, the one developed indigenously by Bharat Biotech in collaboration with ICMR and the one developed by Zydus Cadila Ltd, are in phase 2 of human clinical trials.
The Pune-based Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford COVID-19 candidate vaccine, is also conducting Phase 2 and 3 human clinical trials in India.
There is growing hope that health regulators will give a green light for a coronavirus vaccine later this year to roll out into a vaccination program in six months or even less, according to a report by UK media. .
The candidate vaccine being tested by scientists at the University of Oxford in collaboration with the pharmaceutical giant AstraZeneca is the most advanced in the testing process and, according to a report by ‘The Times’, could receive the necessary authorizations by Christmas in December .
The newspaper quoted UK government sources involved in vaccine manufacturing and distribution as saying that a full adult vaccine rollout program could take six months or less after approval.
“We’re looking at about six months and it’s likely to be much shorter than that,” a government source said, PTI reported.
Hyderabad-based Dr Reddy’s Laboratories applied to India’s Controller General of Drugs for permission to conduct phase 3 human clinical trials of the Russian Sputnik V vaccine against COVID-19 in India, sources said.
The Indian pharmaceutical giant has collaborated with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V, as well as its distribution.
Following regulatory approval in India, RDIF will supply drug maker Dr. Reddy with 100 million doses of the vaccine, the firm said last month.
“Dr. Reddy’s Laboratories has requested permission from DCGI to conduct phase 3 human clinical trials of the Russian-developed Sputnik V vaccine against COVID-19. DCGI will conduct a technical evaluation of the application prior to giving approval.” a source told PTI.
The number of COVID-19 cases in India exceeded 65 lakh, while the number of people who have recovered from the disease exceeded 55 lakh, according to data from the Union Ministry of Health updated on Sunday.
The recovery rate stands at 84.13%.
Total coronavirus cases amounted to 65,49,373 with 75,829 people testing positive for the infection in one day, while the death toll rose to 1,01,782 and the virus claimed 940 lives in a 24-hour span, the researchers showed. data updated at 8 am. .
Total recoveries rose to 55,09,966, while there are 9,37,625 active cases of coronavirus infection in the country, accounting for 14.32 percent of total cases, according to the data.
The COVID-19 fatality rate has dropped further to 1.55 percent.
India’s COVID-19 count had crossed the 20 lakh mark on August 7, 30 lakh on August 23, and 40 lakh on September 5. It went from 50 lakh on September 16 and crossed 60 lakh on September 28.
According to the ICMR, until October 3 a cumulative total of 7,89,92,534 samples have been analyzed and on Saturday 11,42,131 samples have been analyzed.
.
